Results of a multi-center phase II study of imatinib and fluorourcail/leucovorin (FU/LV) in patients with unresectable or metastatic gallbladder or biliary tract cancer

被引：0
|
作者：
Schuette, K. [1 ]
Moehler, M. [2 ]
Kettner, E. [3 ]
Hegewisch-Becker, S. [4 ]
Goekkurt, E. [1 ]
Al-Batran, S. [5 ]
Steffens, C. [6 ]
Ehninger, G. [1 ]
Stoehlmacher, J. [1 ]
机构：
[1] Univ Klinikum Carl Gustav Carus, Med Klin 1, Dresden, Germany
[2] Univ Mainz Klinikum, Med Klin, Mainz, Germany
[3] Klinikum Magdeburg, Magdeburg, Germany
[4] Onkol Schwerpunkt Praxis Hamburg, Hamburg, Germany
[5] Krankenhaus Nordw, Med Klin 2, Frankfurt, Germany
[6] Onkol Praxisgemeinschaft, Stade, Germany
来源：
EJC SUPPLEMENTS | 2009年 / 7卷 / 02期
关键词：
D O I：
10.1016/S1359-6349(09)71339-4
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：395 / 395
页数：1
相关论文
共 50 条
  • [21] A phase II study of oxaliplatin and capecitabine (XELOX) in patients with unresectable cholangiocarcinoma, including carcinoma of the gallbladder and biliary tract.
    Glover, KY
    Thomas, MB
    Brown, TD
    Hoff, PM
    Iwasaki, M
    Abbruzzese, JL
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 338S - 338S
  • [22] Multi-center phase II study of irinotecan+5-FU/L-LV (RPMI) chemotherapy for patients with metastasic colorectal cancer (OGSG0201)
    Mishima, H.
    Ikenaga, M.
    Ishida, H.
    Iwamoto, S.
    Morimoto, T.
    Narahara, H.
    Kato, T.
    Tsujinaka, T.
    Furukawa, H.
    Taguchi, T.
    ANNALS OF ONCOLOGY, 2006, 17 : 75 - 75
  • [23] Multi-center phase II study of irinotecan+5-FU/I-LV (RPMI) chemotherapy for patients with metastasic colorectal cancer (OGSGO201)
    Mishima, H
    Ishida, H
    Iwamoto, S
    Morimoto, T
    Kato, T
    Tsujinaka, T
    Furukawa, H
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 295S - 295S
  • [24] Phase II study of salvage mFOLFOX (5-fluorouracil, leucovorin, oxaliplatin) in patients with unresectable biliary tract cancer who had failed gemcitabine
    Hwang, I.
    Jang, J. S.
    Oh, S. Y.
    Sun, J. M.
    Nam, E. M.
    Lee, H. R.
    Jun, H. J.
    Chi, K. C.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S630 - S630
  • [25] Phase II study of S-1 in patients with unresectable or recurrent biliary tract cancer (BTC)
    Boku, N.
    Okusaka, T.
    Furuse, J.
    Ohkawa, S.
    Yamao, K.
    Masumoto, T.
    Funakoshi, A.
    ANNALS OF ONCOLOGY, 2006, 17 : 318 - 318
  • [26] Efficacy and biomarker analysis of nivolumab plus gemcitabine and cisplatin in patients with unresectable or metastatic biliary tract cancers: results from a phase II study
    Feng, Kaichao
    Liu, Yang
    Zhao, Yongtian
    Yang, Qingming
    Dong, Liang
    Liu, Jiejie
    Li, Xiang
    Zhao, Zhikun
    Mei, Qian
    Han, Weidong
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 (01)
  • [27] Phase II study of mFOLFOX3 (5-fluorouracil, leucovorin, oxaliplatin) as second-line treatment after gemcitabine failure in patients with unresectable/metastatic biliary tract cancer
    In Gyu Hwang
    Joung-Soon Jang
    Sung Yong Oh
    Myung Hwan Rho
    Suee Lee
    Young Suk Park
    Joon Oh Park
    Eun Mi Nam
    Hyo Rak Lee
    Hyun Jung Jun
    Kyong-Choun Chi
    Cancer Chemotherapy and Pharmacology, 2015, 75 : 757 - 762
  • [28] Phase II study of mFOLFOX3 (5-fluorouracil, leucovorin, oxaliplatin) as second-line treatment after gemcitabine failure in patients with unresectable/metastatic biliary tract cancer
    Hwang, In Gyu
    Jang, Joung-Soon
    Oh, Sung Yong
    Rho, Myung Hwan
    Lee, Suee
    Park, Young Suk
    Park, Joon Oh
    Nam, Eun Mi
    Lee, Hyo Rak
    Jun, Hyun Jung
    Chi, Kyong-Choun
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2015, 75 (04) : 757 - 762
  • [29] Phase II trial of imatinib mesylate in patients with metastatic. unresectable pancreatic cancer.
    Gharibo, MM
    Juvidian, P
    Patrick-Miller, L
    Zheng, L
    Craig, J
    Guensch, L
    Wojtaszek, C
    Poplin, E
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 353S - 353S
  • [30] A phase II study of 5-FU (F), leucovorin (LV), etoposide (E) and α-interferon (I) in advanced gastric cancer patients
    Destefanis, M
    Capello, C
    Satolli, MA
    Dalla Mola, A
    Castiglione, F
    Miglietta, L
    Marenco, D
    Porcile, G
    Alabiso, O
    ANNALS OF ONCOLOGY, 1998, 9 : 54 - 55
12345